Citi analyst Joanne Wuensch lowered the firm’s price target on Baxter to $38 from $44 and keeps a Neutral rating on the shares. The firm says the Q1 earnings season volatility creates opportunity in the medical technology space. The U.S. hospital capital purchasing environment is stable and China remains a point of volatility through anti-corruption policies and stimulus packages, the analyst tells investors in a research note. Citi left Boston Scientific (BSX) as a top pick while removing Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG). The firm also added GE HealthCare (GEHC) as it recovers from a Q1 low and Insulet (PODD) as it expects a stronger second half of 2024 and momentum into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter put volume heavy and directionally bearish
- Baxter says Vantive separation expected in second half of 2024
- FDA approves Baxter’s Clinolipid neonatal and pediatric Iindication
- Warner Bros. upgraded, Cerence downgraded: Wall Street’s top analyst calls
- Baxter downgraded to Hold from Buy at TD Cowen